髓源性抑制细胞对炎症性肠病的免疫调节作用及靶向免疫治疗研究

Immunomodulatory roles of myeloid-derived suppressor cells in inflammatory bowel disease:a potential immunotherapy target

髓源性抑制细胞(myeloid-derived suppressor cells,MDSCs)是机体在缺氧、炎症、感染和癌症等病理条件下,髓系细胞分化受阻的一组异质性未成熟细胞,具有强大的免疫抑制功能。在小鼠和人类中研究表明,MDSCs在炎症肠病(inflammatory bowel disease,IBD)中激活和扩增,通过抑制炎症反应改善IBD的疾病进展,或通过促炎反应加速IBD的发生、发展。因此,了解MDSCs的生物学特性及其在IBD肠道炎症微环境中的调节作用,对靶向MDSCs的免疫治疗至关重要。现就MDSCs在IBD炎症条件下的不同生理作用,包括其促炎或免疫抑制作用以及目前基于MDSCs的免疫治疗策略作一概述,旨在为临床更全面的靶向MDSCs免疫治疗提供理论依据。

Myeloid-derived suppressor cells(MDSCs)are a group of heterogeneous immature cells with strong immunosuppressive potency.These cells generated when differentiation of myeloid cells was inhibited under pathological conditions such as hypoxia,inflammation,infection and cancer.Studies in mice and humans have shown that MDSCs are activated and proliferated in inflammatory bowel disease(IBD),alleviating the disease progression through anti-inflammatory activities,or accelerating the development of IBD by pro-inflammatory responses.Therefore,understanding the biological characteristics of MDSCs and their regulatory mechanism in IBD intestinal inflammatory microenvironment is crucial for immunotherapy targeting MDSCs.This paper reviews differential physiological roles of MDSCs in IBD inflammation,including their pro-or anti-inflammatory effects,as well as current MDSCs-based immunotherapy strategies,in order to provide a more comprehensive theoretical basis for clinical immunotherapy targeting MDSCs.